EP1986674A4 - Compositions protéiques ou peptidiques protéine contenant de la méthionine et leur procédé de fabrication et d'utilisation - Google Patents

Compositions protéiques ou peptidiques protéine contenant de la méthionine et leur procédé de fabrication et d'utilisation

Info

Publication number
EP1986674A4
EP1986674A4 EP07750726A EP07750726A EP1986674A4 EP 1986674 A4 EP1986674 A4 EP 1986674A4 EP 07750726 A EP07750726 A EP 07750726A EP 07750726 A EP07750726 A EP 07750726A EP 1986674 A4 EP1986674 A4 EP 1986674A4
Authority
EP
European Patent Office
Prior art keywords
methionine
making
methods
containing protein
peptide compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07750726A
Other languages
German (de)
English (en)
Other versions
EP1986674A2 (fr
Inventor
Thomas E Tarara
Cynthia Stevenson
Stewart Thompson
Reinhard Vehring
Negar Sadrzadeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of EP1986674A2 publication Critical patent/EP1986674A2/fr
Publication of EP1986674A4 publication Critical patent/EP1986674A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP07750726A 2006-02-13 2007-02-13 Compositions protéiques ou peptidiques protéine contenant de la méthionine et leur procédé de fabrication et d'utilisation Withdrawn EP1986674A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77338406P 2006-02-13 2006-02-13
PCT/US2007/003905 WO2007095288A2 (fr) 2006-02-13 2007-02-13 Compositions protéiques ou peptidiques protéine contenant de la méthionine et leur procédé de fabrication et d'utilisation

Publications (2)

Publication Number Publication Date
EP1986674A2 EP1986674A2 (fr) 2008-11-05
EP1986674A4 true EP1986674A4 (fr) 2009-11-11

Family

ID=38372110

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07750726A Withdrawn EP1986674A4 (fr) 2006-02-13 2007-02-13 Compositions protéiques ou peptidiques protéine contenant de la méthionine et leur procédé de fabrication et d'utilisation

Country Status (2)

Country Link
EP (1) EP1986674A4 (fr)
WO (1) WO2007095288A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1933863A4 (fr) * 2005-09-06 2010-06-09 Zelos Therapeutics Inc Analogues de l'hormone parathyroidienne et procedes les utilisant
WO2008145323A1 (fr) * 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Formulation pharmaceutique comprenant des interférons
NZ586590A (en) 2008-01-09 2012-06-29 Sanofi Aventis Deutschland Insulin analogues or derivatives having an extremely delayed time-action profile
JP5364310B2 (ja) * 2008-07-14 2013-12-11 アルフレッサファーマ株式会社 反応性物質が結合した微小粒子の安定化方法および該微小粒子含有試薬
PT3228320T (pt) 2008-10-17 2020-03-26 Sanofi Aventis Deutschland Combinação de uma insulina e de um agonista do glp-1
MY180661A (en) 2009-11-13 2020-12-04 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
AU2010317994B2 (en) 2009-11-13 2014-03-06 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist and methionine
FR2954325B1 (fr) * 2009-12-23 2012-02-03 Flamel Tech Sa Polymere amphiphile fonctionnalise par la methionine
EP2364690A1 (fr) * 2010-02-12 2011-09-14 Centro De Ingenieria Genetica Y Biotecnologia Granulé pharmaceutique pouvant être administré par voie orale du facteur de croissance épidermique
US20140148384A1 (en) 2010-08-30 2014-05-29 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
KR101787956B1 (ko) * 2011-06-07 2017-10-18 아사히 가세이 파마 가부시키가이샤 고순도 ｐｔｈ 함유 동결 건조 제제 및 그의 제조 방법
RS58456B1 (sr) * 2011-08-01 2019-04-30 Univ Monash Postupak i formulacije za inhalaciju
BR112014004726A2 (pt) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
CA3113172A1 (en) * 2013-03-13 2014-10-02 Genentech, Inc. Screen for compound that prevents protein oxidation based on comparison with l-tryptophan
AR095398A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida
AU2015205621A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
SG11201604706TA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized pharmaceutical formulations of insulin aspart
JP6641280B2 (ja) 2014-01-09 2020-02-05 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
DK3212212T3 (da) 2014-10-31 2020-12-21 Univ Monash Pulverformulering
EP3229828B1 (fr) 2014-12-12 2023-04-05 Sanofi-Aventis Deutschland GmbH Formulation à rapport fixe d'insuline glargine/lixisenatide
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
WO1994007514A1 (fr) * 1992-09-29 1994-04-14 Inhale Therapeutic Systems Liberation dans les poumons de fragments actifs d'hormone parathyroidienne
US6541450B1 (en) * 1994-06-20 2003-04-01 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
WO2005000267A2 (fr) * 2003-05-28 2005-01-06 Nektar Therapeutics Produit pharmaceutique formule comprenant un principe actif insoluble dans l'eau

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
ES2343124T3 (es) * 1999-10-29 2010-07-23 Novartis Ag Composiciones de polvo seco con dispersabilidad mejorada.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
WO1994007514A1 (fr) * 1992-09-29 1994-04-14 Inhale Therapeutic Systems Liberation dans les poumons de fragments actifs d'hormone parathyroidienne
US6541450B1 (en) * 1994-06-20 2003-04-01 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
WO2005000267A2 (fr) * 2003-05-28 2005-01-06 Nektar Therapeutics Produit pharmaceutique formule comprenant un principe actif insoluble dans l'eau

Also Published As

Publication number Publication date
EP1986674A2 (fr) 2008-11-05
WO2007095288A2 (fr) 2007-08-23
WO2007095288A3 (fr) 2008-07-03

Similar Documents

Publication Publication Date Title
EP1986674A4 (fr) Compositions protéiques ou peptidiques protéine contenant de la méthionine et leur procédé de fabrication et d'utilisation
IL262205A (en) Protein formulations and methods for their preparation
HK1249115A1 (zh) 肽序列和組合物
HK1216486A1 (zh) 蛋白飲料及其製備方法
HK1122196A1 (en) Protein hydrolysates and method of making
EP2102355A4 (fr) Protéines et peptides à action prolongée et procédés de production et d'utilisation de ces derniers
IL209386A0 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
EP1987068A4 (fr) Modification des oligosaccharides et marquage des protéines
PL1940240T3 (pl) Kompozycje izolatu białka i ich zastosowania
IL190748A0 (en) Methods and compositions comprising non-natural amino acids
IL187617A0 (en) Lkktet and/or lkktnt peptide compositions and methods
IL197501A0 (en) Modifications of cupredoxin derived peptides and methods of use thereof
EP2029799A4 (fr) Protéines thermostables et procédés pour les préparer et les utiliser
EP2109673A4 (fr) Procedes et compositions pour l'expression et la purification de proteines ameliorees
EP2234636A4 (fr) Formulations de peptides et de protéines stabilisées
PL1998790T3 (pl) Kompozycje zawierające peptydy z aminokwasami niewystępującymi w przyrodzie i sposoby stosowania
EP1789066A4 (fr) Compositions et methodes d'utilisation de peptides inhibiteurs de la croissance de l'alpha-fetoproteine
PL2392587T3 (pl) Sekwencje i kompozycje peptydów
AU2006901628A0 (en) Site-selective derivatisation of peptides and proteins
GB0602416D0 (en) Peptide sequences and compositions
GB0614260D0 (en) Peptide sequences and compositions
GB0604920D0 (en) Peptide sequences and compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080818

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TARARA, THOMAS, E.

Inventor name: STEVENSON, CYNTHIA

Inventor name: THOMPSON, STEWART

Inventor name: VEHRING, REINHARD

Inventor name: SADRZADEH, NEGAR

A4 Supplementary search report drawn up and despatched

Effective date: 20091014

17Q First examination report despatched

Effective date: 20100209

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100820